VivoSim LabsFRA:4OR 38 Equity-to-Asset is 0.64 as of Dec. 2025, which is 29% below its 10-year median of 0.90. GuruFocus rates FRA:4OR with a GF Score™ of 38/100 and a GF Value™ of €10.53. The stock has 4 warning signs investors should review. Among 1,415 Biotechnology companies, VivoSim Labs ranks worse than 54.84% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. VivoSim Labs's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €3.79 Mil. VivoSim Labs's Total Assets for the quarter that ended in Dec. 2025 was €5.94 Mil.
Therefore, VivoSim Labs's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.64.
The historical rank and industry rank for VivoSim Labs's Equity-to-Asset or its related term are showing as below:
FRA:4OR'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.1 Med: 0.9 Max: 0.98
Current: 0.64
During the past 13 years, the highest Equity to Asset Ratio of VivoSim Labs was 0.98. The lowest was 0.10. And the median was 0.90.
FRA:4OR's Equity-to-Asset is ranked worse than 54.84% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs FRA:4OR: 0.64
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
VivoSim Labs Equity-to-Asset Related Terms
VivoSim Labs Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs SLXN, CDT, CLDI: Equity-to-Asset Comparison
For the Biotechnology subindustry, VivoSim Labs's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
VivoSim Labs's Equity to Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a Equity-to-Asset of 0.64 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on VivoSim Labs and its competitors. This is 29% below median its historical median of 0.90. Over the past decade, VivoSim Labs' Equity-to-Asset has ranged from 0.10 to 0.98. According to the industry distribution chart, VivoSim Labs ranks #776 out of 1415 companies in the Biotechnology industry, placing it in the top 54.8%.
Is VivoSim Labs' Equity-to-Asset too high?
VivoSim Labs' current Equity-to-Asset of 0.64 is 29% below median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 0.98. The Biotechnology industry median Equity-to-Asset is 0.68. VivoSim Labs' value of 0.64 is 5.9% below this industry median. Based on the distribution chart, VivoSim Labs ranks #776 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Equity-to-Asset compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #776 out of 1415 companies for Equity-to-Asset. This places VivoSim Labs in the lower half of its industry. The industry median Equity-to-Asset is 0.68. VivoSim Labs' value of 0.64 is 5.9% below this benchmark. Historically, VivoSim Labs' own Equity-to-Asset has ranged from 0.10 to 0.98 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 0.68, VivoSim Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current Equity-to-Asset of 0.64 is 5.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current Equity-to-Asset is 0.64, which is 29% below median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Equity-to-Asset of 0.64. The stock's GF Value™ is €10.53, compared to a current price of €3.49 — trading 66.8% below its estimated fair value. The current Equity-to-Asset is 0.64, which is 29% below median its 10-year median of 0.90 and 5.9% below the Biotechnology industry median of 0.68. VivoSim Labs' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Equity-to-Asset is 0.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 66.8% below its estimated GF Value™ of €10.53.
Key valuation signals for FRA:4OR:
Equity-to-Asset: 0.64 (29% below median its 10-year median of 0.90)
GF Value™: €10.53 vs. price of €3.49 (66.8% below fair value)
Industry Position: 5.9% below the Biotechnology median (#776 of 1415)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
38GF Score
Get the complete analysis for FRA:4OR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
